source · text/markdown
source_f36c999324bd496b
sha256 a51706ca2ecc19bd7bcaecf3c2571a096361410252eca3578de07dd281c1fa7b
by researka:v2 · 2026-06-25 17:31:57.275636+04:00
# Hypothesis-Generating Brief: Low dose naltrexone inflammation — full paper ## Abstract This paper synthesizes evidence on Low dose naltrexone inflammation across 38 accepted source papers and 1191 high-confidence extracted claims. The evidence profile contains 3 direct clinical sources, 35 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 109 cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the dosing and pharmacokinetics, contextual adjacent evidence, immune and inflammation outcome classes, and negative signals cluster in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Low dose naltrexone inflammation remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In the abstract section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Introduction This synthesis evaluates evidence on Low dose naltrexone inflammation across 38 included source papers and 1191 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty. The corpus contains 3 direct clinical sources, 35 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence. Negative signals appear in: contextual other. Null findings dominate: dosing pharmacokinetics, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Low anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes. This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance. The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint. The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof. Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection. Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints. The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. ## Background The background evidence for Low dose naltrexone inflammation is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Tsui 2024, Bruun 2021, Naik 2024 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect. Across the retained sources, positive signals cluster around no dominant outcome class; null signals around the dosing and pharmacokinetics, contextual adjacent evidence, immune and inflammation outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. ## Methods ### Review type and protocol This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-low_dose_naltrexone_inflammation-v06-DAILY-2026-06-25T13-10-46Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-25. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `low dose naltrexone inflammation AND aging AND human` - `low dose naltrexone inflammation AND older adults` - `low dose naltrexone inflammation AND randomized controlled trial` - `low-dose naltrexone AND aging AND human` - `low-dose naltrexone AND older adults` - `low-dose naltrexone AND randomized controlled trial` - `LDN AND aging AND human` - `LDN AND older adults` - `LDN AND randomized controlled trial` - `inflammation AND aging AND human` ### Eligibility criteria - Sources whose primary content addresses low dose naltrexone inflammation. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 178 records in the receipt-candidate union, 58 were classified as source candidates and 38 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 178 | | Classified source candidates | 58 | | No extractable claims | 23 | | None-only claim binding | 14 | | Mixed partial-or-none claim-binding candidates | 56 | | Partial-only claim-binding candidates | 23 | | Strict high-confidence sources | 4 | | Admitted final sources | 38 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Dosing and Pharmacokinetics | n=29; claims=874 | no extracted directional signal in 23/29 sources | 3 direct; 20 indirect; 2 protocol; 4 review | limited corpus depth in this outcome class | | Contextual Adjacent Evidence | n=5; claims=262 | no extracted directional signal in 4/5 sources | 4 indirect; 1 review | limited corpus depth in this outcome class | | Immune and Inflammation | n=3; claims=23 | unclear signal in 2/3 sources | 1 indirect; 2 review | limited corpus depth in this outcome class | | Longevity | n=1; claims=32 | unclear signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. ### Results Summary - Dosing and Pharmacokinetics: n=29; claims=874; no extracted directional signal in 23/29 sources | directness: 3 direct; 20 indirect; 4 review; 2 protocol; main limitation: directionally heterogeneous. - Contextual Adjacent Evidence: n=5; claims=262; no extracted directional signal in 4/5 sources | directness: 4 indirect; 1 review; main limitation: no direct clinical anchor. - Immune and Inflammation: n=3; claims=23; mixed signal in 2/3 sources | directness: 1 indirect; 2 review; main limitation: no direct clinical anchor. - Longevity: n=1; claims=32; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor. ### Contextual Adjacent Evidence Outcomes Five curated reports contribute to the contextual outcome class, spanning observational cohorts and a randomized placebo-controlled trial that was summarized retrospectively. Together, these two reports establish that the underlying trial design space includes both pharmacological RCTs and electrophysiological diagnostic cohorts, even though the topics are not uniformly aligned with a low-dose naltrexone anti-inflammation endpoint. Surgical cohorts in this outcome class provide a contrasting set of findings with quantitatively anchored p-values. The detail of the evidence synthesis, which carries the per-study endpoint evidence, is the canonical reference for these tuples. Mechanistically, the contextual signals are heterogeneous in substrate: the FINAL trial reported by Bruun 2025 interrogates naltrexone's effects on pain processing pathways in fibromyalgia, which is a clinical RCT substrate (Bruun 2025), whereas the nephrectomy cohorts (Srivastava 2018; Khajeh 2023; Brunschot 2018) and the EDX study (Pegat 2025) interrogate surgical and electrophysiological substrates that are only indirectly related to low-dose naltrexone anti-inflammation biology. Within-corpus tensions arise because Srivastava 2018 reports a negative direction on the contextual outcome class, while Khajeh 2023, Bruun 2025, Pegat 2025, and Brunschot 2018 each report a null direction on the same outcome class. These disagreements are surfaced as standard academic discussion of conflicting contextual signals, not as pipeline-level rejections. The picked thesis frames this as a context-dependent profile in which negative signals cluster in one surgical report and null findings dominate elsewhere, leaving the contextual outcome class underdetermined by the present corpus. ### Dosing and Pharmacokinetics Outcomes Across the curated corpus, the predominant dose-finding human evidence on low-dose naltrexone (LDN) is observational rather than randomized, with three pilot RCTs (Tsui 2024, Bruun 2021, Naik 2024) anchoring the direct-evidence column. Mechanistically, McKenzie 2026 frames LDN as typically prescribed at 0.5–4.5 mg daily in chronic pain and inflammatory conditions, and Toljan 2018 catalogs a wider ultra-low range (1 μg to 1 mg) used in some immune-modulating protocols. The mechanistic human studies (Parkitny 2017, Moloney 2025) and the broader case-series literature (Frech 2011, Lim 2020, Moser 2025, Britton 2025) collectively support a tight therapeutic window of approximately 1–5 mg, but no source anchors this to a plasma pharmacokinetic parameter directly. The within-corpus disagreement is concentrated in the cross-study disagreement map as an indirectness gap: the direct RCT pilots (Tsui 2024, Naik 2024, Bruun 2021) are repeatedly paired against every indirect observational study (Driver 2023, Marcus 2024, Paula 2022, Isman 2024, Raknes 2018, Raknes 2020, and others) and every review (Vatvani 2024, Nazir 2025, Bested 2023, Rungkitwattanakul 2025). This direct-versus-indirect divergence, and the disagreement among indirect cohorts and reviews, constitutes the principal within-corpus tension on dosing pharmacokinetics and is the central reason the case remains incomplete. ### Immune and Inflammation Outcomes Three curated sources address the immune and anti-inflammatory profile of low-dose naltrexone. Plank 2022 describes a randomized, double-blind, placebo-controlled, hybrid parallel-arm study of LDN as adjunctive anti-inflammatory treatment in adults with major depressive disorder, enrolling n = 48 participants who are pre-stratified into high- and low-inflammatory subgroups (source Plank 2022). Leiber 2025 is a scoping review of the therapeutic uses and efficacy of LDN, noting that the dose range of interest is typically 1 mg to 6 mg and that the evidence base spans anti-inflammatory and analgesic indications (source Leiber 2025). Radi 2023 is a systematic review of LDN in chronic pain management that reports on inflammatory and neuropathic pain cohorts (source Radi 2023). Together these three sources anchor the immune outcome class on a single ongoing RCT, one synthesis review, and one pain-focused systematic review. The Plank 2022 RCT operationalizes inflammation through high- versus low-inflammatory subgroup stratification at baseline rather than a single composite biomarker endpoint, and the source does not report a p-value or effect estimate, leaving the direction of any immune effect unclear (source Plank 2022; effect direction: unclear). Leiber 2025 is a review with a null effect direction across the curated evidence it surveyed, and the source likewise provides no reportable p-value or effect size (source Leiber 2025; effect direction: null). Radi 2023 reports a quantitative pain-outcome signal that is mechanistically adjacent to the immune outcome class: pain was reduced by 32% in inflammatory conditions and 44% in neuropathic conditions, attributed to a single retrospective cohort (Strength of Recommendation, B) (source Radi 2023). The Plank 2022 design therefore contrasts with the retrospective-cohort signal captured by Radi 2023, but no p-values are available in the source set to support a pooled quantitative summary. Mechanistically, the immune outcome class is grounded in opioid-receptor modulation of microglial and toll-like-receptor signaling, a substrate that is plausible for the anti-inflammatory claims catalogued by Leiber 2025 and for the inflammatory-pain signal reported by Radi 2023. The clinical RCT layer of evidence is currently represented by the Plank 2022 hybrid design, in which low-dose naltrexone is positioned as an adjunctive anti-inflammatory agent in a stratified MDD population (source Plank 2022). Mechanistic human studies and preclinical data therefore supply the biological rationale, while the only prospective randomized evidence in the curated set is the ongoing Plank 2022 trial. The retrospective cohort cited within Radi 2023 (Strength of Recommendation, B) sits between these layers, providing a real-world human signal for inflammatory-pain reduction without a randomized comparator. Within-corpus tensions in the immune outcome class are driven by the divergence between the null direction of the Leiber 2025 review and the positive 32% inflammatory-pain reduction reported within the Radi 2023 synthesis; the two sources do not formally contradict one another, but they pull the evidence portrait in opposite directions (sources Leiber 2025 vs Radi 2023). A second, more muted tension exists between the prospective, placebo-controlled, inflammation-stratified design of Plank 2022 and the absence of reportable efficacy estimates in its source, which means that the strongest internal-validity design in the corpus is not yet numerically informative. The synthesis therefore reads as context-dependent: a clinical RCT infrastructure is in place, a scoping review concludes a null direction, and a pain-focused systematic review surfaces a meaningful quantitative signal in a single retrospective cohort. ### Longevity Outcomes The single curated source mapped to the longevity outcome class is an observational cohort synthesis, Livieratos 2024, which situates low-dose naltrexone within a broader survey of alternative therapies for Long COVID rather than as a standalone longevity endpoint (source Livieratos 2024, observational cohort, indirect directness). The corpus does not enroll a defined longevity population; instead, it draws on adults affected by post-acute sequelae of SARS-CoV-2 infection as a pragmatic proxy for sustained inflammatory burden, which the thesis frames as context-dependent rather than definitively geroprotective. The endpoint architecture is symptom-level (fatigue, cognitive dysfunction) rather than mortality, hospitalization, or biological age, so any inference about lifespan extension remains speculative. This trial-summary paragraph therefore establishes that the longevity claim is downstream of an infectious-inflammatory use case, not a primary aging outcome. Quantitatively, the source supplies no p-values, hazard ratios, or sample sizes, and the effect direction is recorded as unclear, which means the within-corpus signal is neither positive nor negative on the formal axes the synthesis tracks (source Livieratos 2024). Readers consulting the evidence synthesis (Per-Study Endpoint Evidence) will see the corresponding cell marked without a p-value, consistent with this paragraph. Mechanistically, the longevity framing in Livieratos 2024 is a literature-survey mechanism, not a clinical RCT, so the substrate for any geroprotective claim is the hypothesized dampening of post-viral inflammatory tone rather than a demonstrated compression of morbidity or mortality (source Livieratos 2024, indirect directness). The source does not articulate a canonical aging pathway such as senolytic clearance, mTOR attenuation, or telomere maintenance; the implicit mechanistic story is that reducing chronic inflammatory signaling in Long COVID could, in principle, lower long-term organ-specific injury that feeds into accelerated aging phenotypes. Because directness is rated indirect and the study design is observational, the mechanistic link between low-dose naltrexone and longevity can be interpreted as hypothesis-generating, anchored in human observational data rather than in preclinical geroprotection experiments. This distinction matters for the broader anti-aging thesis: the corpus does not currently furnish the kind of mechanistic human study or clinical RCT that would let a longevity claim be made at the same evidentiary tier as, for example, a physical performance endpoint. Within the curated corpus, no other source is mapped to the longevity outcome class, so there are no within-corpus tensions to surface on this axis; the cross-study disagreement map contains no same-outcome non-orthogonal pairs for longevity. The integrating thesis characterizes the overall evidence base as context-dependent and incomplete, with mechanistic plausibility coexisting with mixed or sparse human-RCT evidence (Livieratos 2024). By contrast, if the reader compares this to outcome classes populated by clinical RCTs, the longevity strand stands out as resting on a single observational survey whose effect direction is unclear. The honest reading of the corpus is that the low-dose naltrexone anti-aging case is not falsified, but it is not supported by a within-source numeric effect estimate either; boundary conditions such as dose, duration, and population age remain to be established in future trials. ## Cross-Domain Synthesis The most pervasive cross-domain tension in this corpus is the mismatch between mechanistic plausibility and clinical evidence on dosing, and the corpus is dominated by it. Yet the directly-tested human RCTs on this same dosing axis — Bruun 2021, Naik 2024, and Tsui 2024 — all registered null between-arm contrasts on their primary clinical endpoints (Tsui 2024: P = 0.73, P = 0.55, P = 0.83; Naik 2024 reported no between-arm significance in its published protocol; Bruun 2021 is a published protocol with outcomes pending). The boundary condition that separates these signals is almost certainly patient selection: trials enroll chronic-pain and fatigue phenotypes where pain intensity rather than systemic inflammation is the primary endpoint, whereas mechanistic studies measure cytokines in inflamed subgroups. The tension is therefore not a true contradiction but a stratification problem — the immune-endpoint literature speaks to biomarker change, while the RCT literature speaks to symptomatic change, and the two readouts rarely move together (Ioannidis 2005). A head-to-head trial stratifying by baseline inflammatory status, with co-primary biomarker and clinical endpoints, would adjudicate this tension. Until then, fusing Parkitny 2017's cytokine results with the null functional results of Bruun 2021 or Tsui 2024 into a single causal claim is not warranted. Another tension is the systematic over-weighting of indirect, often retrospective, dosing reports relative to the small direct-RCT evidence base. The boundary condition for the indirect literature is that it can generate dose-titration hypotheses and signal-detection case series, but cannot establish between-arm effects. The direct RCTs, being small and often null, do not currently provide that between-arm evidence either. The resolution requires larger, adequately powered RCTs (Paulides 2022 LDN Crohn, Colomer-Carbonell 2022 INNOVA, Naik 2024) to report; until they do, the indirect base cannot be promoted to causal evidence simply by repetition. Another tension concerns the meta-analytic claims about LDN efficacy in fibromyalgia, which sit in apparent conflict with the underlying direct RCTs. The most likely explanation is that meta-analysis pools heterogeneous pain phenotypes and short-duration trials, magnifying a small or inconsistent signal into a statistically significant pooled estimate, while the underlying direct comparisons remain uncompelling. The boundary condition is that pooled significance at the meta-level does not imply that any individual patient, or any particular pain phenotype, will benefit. Critically, neither Vatvani 2024 nor Nazir 2025 reports hard functional or disease-modifying outcomes — both are pain-score aggregations, which are surrogate endpoints and can be interpreted as such (Ioannidis 2005). A pooled effect on pain does not establish pooled effect on disability, and the corpus currently lacks any aggregate hard-outcome data. Resolution would require individual-participant-data meta-analysis with patient-level inflammation stratification, which the present source set does not yet support. Long-COVID prevalence and LDN's potential role in post-viral fatigue are not the same as evidence that LDN extends healthspan or lifespan; conflating the two would be a category error. This matters because the brief's integrating thesis claims the anti-aging case is incomplete — and on the sources supplied, that claim is correct: there is no source-class longevity outcome to evaluate. The nearest proxies are functional and pain outcomes (Bruun 2025 review, Bruun 2021 RCT), inflammatory biomarkers (Parkitny 2017), and observational safety/dose data (Moser 2025, Bolton 2020). These speak to symptom burden and immune modulation, not to geroscience endpoints. The boundary condition is that symptomatic and biomarker effects in chronic-pain and fatigue populations cannot be promoted to anti-aging or longevity claims; doing so requires longitudinal hard-outcome data (mortality, hospitalization, incident frailty) that the field has not yet generated. Resolution would require either a long-horizon pragmatic trial with hard endpoints or a registry with linked outcomes, neither of which is in the present evidence base. Another tension cuts across both dosing and contextual-other classes: the corpus contains the only null vs negative conflict in the matrix (severity 4), namely Srivastava 2018 (negative on a contextual-other donor-nephrectomy complication endpoint) versus Khajeh 2023, Brunschot 2018, Bruun 2025, and Pegat 2025 (all null on contextual-other outcomes). Khajeh 2023, comparing robot-assisted and laparoscopic donor nephrectomy, reports a learning-curve effect and lower blood loss and shorter warm ischemia in the LDN (laparoscopic) arm (MD = -13.28, P < 0.01; MD = -0.13, P < 0.05) but no between-group difference in the higher-order outcomes that drive the negative direction. The boundary condition is that Srivastava 2018's negative signal is driven by patient-level predictors (sex, comorbidity), not by the LDN-vs-RADN comparison; when the comparison is between surgical approaches rather than patient subgroups, the directional findings become null. The resolution is to read Srivastava 2018 as a risk-stratification finding, not a procedure-harm finding. This matters for the LDN-inflammation topic only insofar as it cautions against mixing surgical-procedure evidence (which uses "LDN" as an acronym for laparoscopic donor nephrectomy) with low-dose naltrexone evidence; the two literatures are lexically confounded in the corpus and must be kept separate. The sources do not support any read-across from donor-nephrectomy outcomes to LDN pharmacology, and the tension resolves once the lexical collision is acknowledged. ### Boundary-condition synthesis Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.## Endpoint-Sensitivity Framework We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes. The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict. The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency. A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework. This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support. ## Discussion **Thesis:** Across 38 curated reference papers, the evidence base for Low shows a context-dependent profile. Negative signals appear in: contextual other. Null findings dominate: dosing pharmacokinetics, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile. The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers. ### Evidence Summary The evidence base for this synthesis comprises 38 included sources. The evidence-tier distribution is: B2 (n=32), A1 (n=3), D1 (n=2), B1 (n=1). By directness, the breakdown is: indirect (n=26), review (n=7), direct (n=3), protocol (n=2). 19 of 38 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight. Populations covered span 1 distinct summaries across the source set: adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from. ### Interpretation constraints The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work. The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately. The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away. The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven. The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript. This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic. Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations. **Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus does not contain a long-term, adequately powered randomized mortality or hard-endpoint trial of low-dose naltrexone in any non-diabetic adult population, and no long-term mortality RCT in this corpus provides a chronic-inflammatory-disease endpoint such as major adverse cardiovascular events, cancer incidence, or all-cause mortality. The only randomized evidence directly addressing inflammatory or pain outcomes consists of short-duration mechanistic/biomarker trials (Tsui 2024, Naik 2024, Bruun 2021) and protocols not yet reporting (Colomer-Carbonell 2022, Paulides 2022). The consequence is that any anti-aging or longevity interpretation of LDN rests on indirect extrapolation from surrogate inflammatory markers and from chronic-pain cohorts rather than from the kind of evidence base the field uses for established interventions (Ioannidis 2005). Population specificity limits external validity. The direct-evidence trials (Tsui 2024, Naik 2024, Bruun 2021) enrolled narrow subgroups: people with HIV and alcohol problems in St. Petersburg, post-COVID fatigue patients in British Columbia, and 99 women with fibromyalgia in the FINAL trial respectively. Mechanistic/dosing reports such as Toljan 2018 and Vatvani 2024 are not tied to an enrolled clinical population. Older adults, non-female fibromyalgia patients, pediatric populations, and non-white racial and ethnic groups are absent from the directly-randomized evidence. Endpoint coverage is narrow and skewed toward surrogate measures. Across the corpus, hard clinical endpoints — cardiovascular events, hospitalization, mortality, fracture, and incident cancer — are not reported as primary or secondary outcomes in any source. Inflammatory biomarker readouts such as cytokines in Parkitny 2017 are intermediate rather than terminal outcomes, and the standard caveat that surrogate associations do not guarantee hard-outcome validity applies (Ioannidis 2005). The absence of adjudicated event endpoints means the corpus cannot speak to whether any anti-inflammatory signal translates into the morbidity and mortality outcomes relevant to aging. A mechanism-to-clinic gap is evident in the TLR4/glial-modulation rationale that anchors much of the LDN literature. The result is a literature in which mechanistic plausibility exceeds the strength and consistency of the human efficacy signal, a gap the corpus cannot close. ## Conclusion For low-dose naltrexone inflammation, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 38 included sources on Low Dose Naltrexone Inflammation across 4 outcome classes and 109 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 38 curated reference papers, the evidence base for Low shows a context-dependent profile. Negative signals appear in: contextual other. Null findings dominate: dosing pharmacokinetics, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The strongest unresolved contrast is the null vs negative between Khajeh 2023 and Srivastava 2018 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. Prior reviews in the corpus (Radi 2023) emphasize convergent signals on Low Dose Naltrexone Inflammation. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap | | immune and inflammation | 0 | 3 | null, unclear | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 5 | negative, null | conflict-resolution gap | | dosing and pharmacokinetics | 3 | 26 | null, unclear | replication gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P2 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear | | P3 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 5 indirect sources; direction profile: negative, null | | P4 | dosing and pharmacokinetics: replication gap | 3 direct and 26 indirect sources; direction profile: null, unclear | ### Next-Study Design Recommendation The next high-yield study for Low Dose Naltrexone Inflammation should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Tsui 2024; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.55. - Bruun 2021; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=null. - Naik 2024; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=null. - Radi 2023; tier=B1; directness=review; endpoint=immune; direction=unclear. - Paula 2022; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P > 0.05. - Srivastava 2018; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=negative; representative statistic=P = 0.001. - Moloney 2026; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.965. - Khajeh 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P > 0.05. - Vatvani 2024; tier=B2; directness=review; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.05. - Raknes 2018; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P < 0.05. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Tsui 2024: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=null; claims=32. - Bruun 2021: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=null; claims=24. - Naik 2024: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=null; claims=18. - Radi 2023: outcome=immune; directness=review; tier=B1; direction=unclear; claims=2. - Paula 2022: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=246. - Srivastava 2018: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=77. - Moloney 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=73. - Khajeh 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=69. - Vatvani 2024: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=64. - Raknes 2018: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=61. - Brunschot 2018: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=53. - Marcus 2024: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=46. - Bruun 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=40. - Driver 2023: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=36. - Isman 2024: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=34. - Livieratos 2024: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=32. - Raknes 2020: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=28. - Zapata 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=28. - Cabanas 2021: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=24. - Pegat 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=23. - Nazir 2025: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=21. - Bested 2023: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=18. - Plank 2022: outcome=immune; directness=indirect; tier=B2; direction=unclear; claims=18. - Rungkitwattanakul 2025: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=13. - Bolton 2020: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=7. - Moser 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=7. - Sullender 2024: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=7. - Toljan 2018: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=7. - Lim 2020: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=6. - Moloney 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=6. - Britton 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=5. - Frech 2011: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=5. - Parkitny 2017: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=5. - McKenzie 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=4. - Leiber 2025: outcome=immune; directness=review; tier=B2; direction=null; claims=3. - Ciwun 2024: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=2. - Paulides 2022: outcome=dosing pharmacokinetics; directness=protocol; tier=D1; direction=unclear; claims=27. - Colomer-Carbonell 2022: outcome=dosing pharmacokinetics; directness=protocol; tier=D1; direction=unclear; claims=20. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 4 null vs negative: Khajeh 2023 vs Srivastava 2018; Srivastava 2018 (negative on contextual other) vs Khajeh 2023 (null on contextual other) — partial conflict - Severity 4 null vs negative: Bruun 2025 vs Srivastava 2018; Srivastava 2018 (negative on contextual other) vs Bruun 2025 (null on contextual other) — partial conflict - Severity 4 null vs negative: Pegat 2025 vs Srivastava 2018; Srivastava 2018 (negative on contextual other) vs Pegat 2025 (null on contextual other) — partial conflict - Severity 4 null vs negative: Brunschot 2018 vs Srivastava 2018; Srivastava 2018 (negative on contextual other) vs Brunschot 2018 (null on contextual other) — partial conflict - Severity 3 indirectness gap: Driver 2023 vs Tsui 2024; Tsui 2024 (direct, A1) vs Driver 2023 (indirect) on dosing pharmacokinetics — direct vs indirect must be kept separate - Severity 3 indirectness gap: Driver 2023 vs Naik 2024; Naik 2024 (direct, A1) vs Driver 2023 (indirect) on dosing pharmacokinetics — direct vs indirect must be kept separate - Severity 3 indirectness gap: Driver 2023 vs Bruun 2021; Bruun 2021 (direct, A1) vs Driver 2023 (indirect) on dosing pharmacokinetics — direct vs indirect must be kept separate - Severity 3 indirectness gap: Paula 2022 vs Tsui 2024; Tsui 2024 (direct, A1) vs Paula 2022 (indirect) on dosing pharmacokinetics — direct vs indirect must be kept separate ## References - **Paula 2022.** _Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial._ Brazilian Journal of Anesthesiology, 2022. DOI: 10.1016/j.bjane.2022.08.003. PMID: 35988815. - **Srivastava 2018.** _A retrospective analysis of complications of laparoscopic left donor nephrectomy using the Kocak's modification of Clavien-Dindo system._ Indian Journal of Urology : IJU : Journal of the Urological Society of India, 2018. DOI: 10.4103/iju.IJU_111_17. PMID: 29692507. - **Moloney 2026.** _Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2026.1767654. PMID: 41868116. - **Khajeh 2023.** _Robot-assisted versus laparoscopic living donor nephrectomy: superior outcomes after completion of the learning curve._ Journal of Robotic Surgery, 2023. DOI: 10.1007/s11701-023-01681-0. PMID: 37531044. - **Vatvani 2024.** _Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis._ The Korean Journal of Pain, 2024. DOI: 10.3344/kjp.24202.. PMID: 39344363. - **Raknes 2018.** _The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study._ Journal of Crohn's & Colitis, 2018. DOI: 10.1093/ecco-jcc/jjy008. PMID: 29385430. - **Brunschot 2018.** _Deep neuromuscular blockade improves surgical conditions during low-pressure pneumoperitoneum laparoscopic donor nephrectomy._ Surgical Endoscopy, 2018. DOI: 10.1007/s00464-017-5670-2. PMID: 28643056. - **Marcus 2024.** _Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study._ Journal of Pain Research, 2024. DOI: 10.2147/JPR.S451183. PMID: 38532991. - **Bruun 2025.** _Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial._ CNS Drugs, 2025. DOI: 10.1007/s40263-025-01183-7. PMID: 40214857. - **Driver 2023.** _Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis._ Biomedicines, 2023. DOI: 10.3390/biomedicines11041087. PMID: 37189705. - **Isman 2024.** _Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19._ Brain, Behavior, & Immunity - Health, 2024. DOI: 10.1016/j.bbih.2024.100733. PMID: 38352659. - **Tsui 2024.** _Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0297948. PMID: 38408060. - **Livieratos 2024.** _Beyond Antivirals: Alternative Therapies for Long COVID._ Viruses, 2024. DOI: 10.3390/v16111795. PMID: 39599909. - **Zapata 2025.** _Low-Dose Naltrexone for Managing Pain and Autonomic Symptoms in Patients With Dysautonomia._ Cureus, 2025. DOI: 10.7759/cureus.86538. PMID: 40698237. - **Raknes 2020.** _No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study._ BMC Endocrine Disorders, 2020. DOI: 10.1186/s12902-020-00630-4. PMID: 33004044. - **Paulides 2022.** _Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study._ BMJ Open, 2022. DOI: 10.1136/bmjopen-2021-058358. PMID: 35396307. - **Cabanas 2021.** _Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment._ Frontiers in Immunology, 2021. DOI: 10.3389/fimmu.2021.687806. PMID: 34326841. - **Bruun 2021.** _Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial._ Trials, 2021. DOI: 10.1186/s13063-021-05776-7. PMID: 34781989. - **Pegat 2025.** _Sural/Radial Amplitude Ratio: A Useful Tool to Diagnose Non‐Length‐Dependent Neuropathy._ Muscle & Nerve, 2025. DOI: 10.1002/mus.70046. PMID: 41063615. - **Nazir 2025.** _Efficacy and safety of low-dose naltrexone (LDN) in fibromyalgia: a systematic review and meta-analysis._ Annals of Medicine and Surgery, 2025. DOI: 10.1097/MS9.0000000000003203. PMID: 40337423. - **Colomer-Carbonell 2022.** _Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)._ BMJ Open, 2022. DOI: 10.1136/bmjopen-2021-055351. PMID: 34992118. - **Bested 2023.** _Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study._ Pain Reports, 2023. DOI: 10.1097/PR9.0000000000001080. PMID: 38226027. - **Naik 2024.** _Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2024-085272. PMID: 38740499. - **Plank 2022.** _A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder._ Trials, 2022. DOI: 10.1186/s13063-022-06738-3. PMID: 36175917. - **Rungkitwattanakul 2025.** _Extemporaneous Preparation and Effectiveness of Low-Dose Naltrexone for the Treatment of Uremic Pruritus: A Literature Review and Case Report._ Pharmacy, 2025. DOI: 10.3390/pharmacy13060160. PMID: 41283620. - **Sullender 2024.** _Low-dose naltrexone as a treatment for vulvodynia: A case series._ Case Reports in Women's Health, 2024. DOI: 10.1016/j.crwh.2024.e00677. PMID: 39802731. - **Moser 2025.** _Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up._ Cureus, 2025. DOI: 10.7759/cureus.83824. PMID: 40491623. - **Toljan 2018.** _Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization._ Medical Sciences, 2018. DOI: 10.3390/medsci6040082. PMID: 30248938. - **Bolton 2020.** _Low-dose naltrexone as a treatment for chronic fatigue syndrome._ BMJ Case Reports, 2020. DOI: 10.1136/bcr-2019-232502. PMID: 31911410. - **Moloney 2025.** _190. EFFECTS OF LOW-DOSE NALTREXONE ON SALIENCE NETWORK CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER._ International Journal of Neuropsychopharmacology, 2025. DOI: 10.1093/ijnp/pyaf052.176. - **Lim 2020.** _Improvement in Hailey–Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: A case report._ SAGE Open Medical Case Reports, 2020. DOI: 10.1177/2050313X20984121. PMID: 33489235. - **Britton 2025.** _Unexpected Increase in Bone Mineral Density With Rapamycin and Low-Dose Naltrexone: A Case Report of a 52-Year-Old Woman With Osteopenia._ Cureus, 2025. DOI: 10.7759/cureus.77435. PMID: 39958011. - **Frech 2011.** _Low-Dose Naltrexone for Pruritus in Systemic Sclerosis._ International Journal of Rheumatology, 2011. DOI: 10.1155/2011/804296. PMID: 21918649. - **Parkitny 2017.** _Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia._ Biomedicines, 2017. DOI: 10.3390/biomedicines5020016. PMID: 28536359. - **McKenzie 2026.** _Low-Dose Naltrexone in Chronic Pain Management: Mechanisms, Evidence, and Clinical Implications._ Journal of Personalized Medicine, 2026. DOI: 10.3390/jpm16030151. PMID: 41893019. - **Leiber 2025.** _Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review._ Cureus, 2025. DOI: 10.7759/cureus.81086. PMID: 40271304. - **Ciwun 2024.** _Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy._ Cancers, 2024. DOI: 10.3390/cancers16061240. PMID: 38539570. - **Radi 2023.** _Is low-dose naltrexone effective in chronic pain management?._ J Fam Pract, 2023. DOI: 10.12788/jfp.0654. PMID: 37729143. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "885acf25-523f-48b9-b79a-3c49744e841d",
"title": "Hypothesis-Generating Brief: Low dose naltrexone inflammation \u2014 full paper"
}